A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
Recent Activity - Last 12 Months
uO Research has been collecting usage data since January 2013. To the best of our ability, this data excludes entries from search engines. Statistics are available at the item, collection and repository level.